サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1663327

シングルユースバイオリアクター - 市場考察、競合情勢、市場予測（2032年）

Single-use Bioreactors - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
シングルユースバイオリアクター - 市場考察、競合情勢、市場予測（2032年）
出版日: 2025年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のシングルユースバイオリアクターの市場規模は、2024年に30億9,217万米ドルであり、2032年までに103億1,591万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで16.33%の成長が見込まれます。

シングルユースバイオリアクターの市場力学

バイオ医薬品産業におけるシングルユース技術の急速な採用が、世界のシングルユースバイオリアクター市場の大きな成長を促進しています。この動向は、コスト効率、汚染リスクの低減、製造の柔軟性向上といった主な利点によって後押しされています。従来のステンレスシステムに比べ、シングルユースバイオリアクターは設備投資が少なく済み、大掛かりな洗浄やバリデーションが不要なため、大幅なコスト削減につながります。これらの利点は、大規模なインフラを整備するリソースが限られている小規模なバイオテクノロジー企業や製造受託機関（CMO）にとって特に価値が高いです。

例えば、スペインのCDMOであるmAbxienceは、2023年4月、レオンの施設にABECの4,000Lシングルユースバイオリアクターを設置し、生産効率を向上させながら運用コストを最小化しました。同様に、WuXi Biologicsは無錫の施設に4,000Lのシングルユースバイオリアクターを複数導入しており、このことは、業界がより安全でコンプライアンスの高いスケーラブルな製造ソリューションへとシフトしていることを示しています。

シングルユースバイオリアクターは使い捨てであるため、バッチ間の二次汚染のリスクが大幅に低減されます。これは、ワクチンやモノクローナル抗体など、些細な汚染でも安全性の懸念や経済的損失につながるデリケートな生物製剤を製造する上で非常に重要な利点です。

こうした要因が、2025年～2032年の予測期間に世界のシングルユースバイオリアクター市場を促進する見込みです。しかし、使い捨てシステムによって発生するプラスチック廃棄物の増加は環境問題を引き起こし、市場成長に対する小さな課題となる可能性があります。

北米がシングルユースバイオリアクター市場全体を独占すると予測される

北米が2024年に世界のシングルユースバイオリアクター市場で最大のシェアを占めると予測されます。この地域の優位性は、Pfizer、Moderna、Amgenなどの先進のバイオプロセス技術の採用を先導する主要企業を有する、その確立されたバイオ医薬品部門によるものです。生物製剤、細胞・遺伝子治療、個別化医療への注目の高まりは、シングルユースバイオリアクターが大きな利点をもたらすこの分野における、柔軟な製造ソリューションへの需要をさらに促進しています。

FDAのような機関による規制支援は技術革新を促し、主要メーカーや研究機関のプレゼンスは製品開発を加速させます。さらに、バイオテクノロジーインフラへの投資の増加や臨床試験の拡大により、スケーラブルで費用対効果の高い生産ソリューションへのニーズが高まっています。

北米におけるシングルユース技術の採用の急増は、これらのシステムが提供する柔軟性、拡張性、運用効率に起因します。バイオ医薬品企業は、シングルユースバイオリアクターを、迅速な生産セットアップやシームレスなバッチ移行、そして規制の厳しい環境における製品の安全性と品質の維持に不可欠な汚染リスクの最小化に活用しています。大掛かりな洗浄と滅菌を必要とする従来のステンレスシステムとは異なり、シングルユースバイオリアクターはダウンタイムと運用コストを削減するため、製造受託機関（CMO）や小規模バイオテクノロジー企業にとって特に魅力的です。

臨床試験や生物製剤の製造がますます小さいバッチサイズや連続処理にシフトする中、シングルユースシステムの多用途性により、企業は進化する生産需要に迅速に対応することができます。米国市場の成長は、新製品のイノベーションによってさらに後押しされます。例えば、米国のAgilitechは、2021年10月にAgilitechバイオリアクターコントローラーを発売しました。このコントローラーは、容量30Lから2,000Lまでのシングルユースバイオリアクターを2台まで管理することができます。

これらの要因を総合すると、北米のシングルユースバイオリアクター市場は予測期間に健全な成長が見込まれます。

当レポートでは、世界のシングルユースバイオリアクター市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 シングルユースバイオリアクター市場レポートのイントロダクション

第2章 シングルユースバイオリアクター市場のエグゼクティブサマリー

  • 市場の概要

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 シングルユースバイオリアクター市場の主な要因の分析

  • シングルユースバイオリアクター市場の促進要因
  • シングルユースバイオリアクター市場の抑制要因と課題
  • シングルユースバイオリアクター市場の機会

第6章 シングルユースバイオリアクター市場のポーターのファイブフォース分析

第7章 シングルユースバイオリアクター市場の評価

  • 容量別
    • 10L
    • 11～100L
    • 101～500L
    • 501～1,500L
    • 1,500L超
  • 製品別
    • システム
    • アクセサリ
  • 用途別
    • 撹拌タンクバイオリアクター
    • 波動誘起バイオリアクター
    • バブルカラムバイオリアクター
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 シングルユースバイオリアクター市場の企業と製品のプロファイル

  • Getinge AB
  • Agilitech
  • WuXi Biologics
  • mAbxience
  • Eppendorf AG
  • Sartorius AG
  • Cytiva Life Sciences
  • Merck KGaA
  • Bionet
  • OmniBRx Biotechnologies
  • Thermo Fisher Scientific Inc.
  • Pall Corporation
  • Distek, Inc.
  • AGC Biologics
  • Celltainer
  • Applikon Biotechnology
  • Biolinx Labsystems
  • Sartorius Stedim Biotech
  • Solaris Biotech
  • Synthecon

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Single-use Bioreactors Market in Global (2022-2032)
  • Table 3: Single-use Bioreactors Market in Global by Capacity(2022-2032)
  • Table 4: Single-use Bioreactors Market in Global by Product (2022-2032)
  • Table 5: Single-use Bioreactors Market in Global by Type (2022-2032)
  • Table 6: Single-use Bioreactors Market in Global by Geography (2022-2032)
  • Table 7: Single-use Bioreactors Market in North America (2022-2032)
  • Table 8: Single-use Bioreactors Market in the United States (2022-2032)
  • Table 9: Single-use Bioreactors Market in Canada (2022-2032)
  • Table 10: Single-use Bioreactors Market in Mexico (2022-2032)
  • Table 11: Single-use Bioreactors Market in Europe (2022-2032)
  • Table 12: Single-use Bioreactors Market in France (2022-2032)
  • Table 13: Single-use Bioreactors Market in Germany (2022-2032)
  • Table 14: Single-use Bioreactors Market in United Kingdom (2022-2032)
  • Table 15: Single-use Bioreactors Market in Italy (2022-2032)
  • Table 16: Single-use Bioreactors Market in Spain (2022-2032)
  • Table 17: Single-use Bioreactors Market in the Rest of Europe (2022-2032)
  • Table 18: Single-use Bioreactors Market in Asia-Pacific (2022-2032)
  • Table 19: Single-use Bioreactors Market in China (2022-2032)
  • Table 20: Single-use Bioreactors Market in Japan (2022-2032)
  • Table 21: Single-use Bioreactors Market in India (2022-2032)
  • Table 22: Single-use Bioreactors Market in Australia (2022-2032)
  • Table 23: Single-use Bioreactors Market in South Korea (2022-2032)
  • Table 24: Single-use Bioreactors Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Single-use Bioreactors Market in the Rest of the World (2022-2032)
  • Table 26: Single-use Bioreactors Market in the Middle East (2022-2032)
  • Table 27: Single-use Bioreactors Market in Africa (2022-2032)
  • Table 28: Single-use Bioreactors Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Single-use Bioreactors Market in Global (2022-2032)
  • Figure 3: Single-use Bioreactors Market in Global by Capacity(2022-2032)
  • Figure 4: Single-use Bioreactors Market in Global by Product (2022-2032)
  • Figure 5: Single-use Bioreactors Market in Global by Type (2022-2032)
  • Figure 6: Single-use Bioreactors Market in Global by Geography (2022-2032)
  • Figure 7: Single-use Bioreactors Market in North America (2022-2032)
  • Figure 8: Single-use Bioreactors Market in the United States (2022-2032)
  • Figure 9: Single-use Bioreactors Market in Canada (2022-2032)
  • Figure 10: Single-use Bioreactors Market in Mexico (2022-2032)
  • Figure 11: Single-use Bioreactors Market in Europe (2022-2032)
  • Figure 12: Single-use Bioreactors Market in France (2022-2032)
  • Figure 13: Single-use Bioreactors Market in Germany (2022-2032)
  • Figure 14: Single-use Bioreactors Market in United Kingdom (2022-2032)
  • Figure 15: Single-use Bioreactors Market in Italy (2022-2032)
  • Figure 16: Single-use Bioreactors Market in Spain (2022-2032)
  • Figure 17: Single-use Bioreactors Market in the Rest of Europe (2022-2032)
  • Figure 18: Single-use Bioreactors Market in Asia-Pacific (2022-2032)
  • Figure 19: Single-use Bioreactors Market in China (2022-2032)
  • Figure 20: Single-use Bioreactors Market in Japan (2022-2032)
  • Figure 21: Single-use Bioreactors Market in India (2022-2032)
  • Figure 22: Single-use Bioreactors Market in Australia (2022-2032)
  • Figure 23: Single-use Bioreactors Market in South Korea (2022-2032)
  • Figure 24: Single-use Bioreactors Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Single-use Bioreactors Market in the Rest of the World (2022-2032)
  • Figure 26: Single-use Bioreactors Market in the Middle East (2022-2032)
  • Figure 27: Single-use Bioreactors Market in Africa (2022-2032)
  • Figure 28: Single-use Bioreactors Market in South America (2022-2032)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Market Opportunities
  • Figure 32: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0861

Single-use Bioreactors Market by Capacity (<=10 L, 11-100 L, 101-500 L, 501-1,500 L, and Above 1,500 L), Product (System and Accessories), Type (Stirred Tank Bioreactors, Wave-Induced Bioreactors, Bubble-Column Bioreactors, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rapid adoption of single-use technologies by the industries, minimal risk of contamination between batches, and growing product development activities across the globe.

The single-use bioreactors market was valued at USD 3,092.17 million in 2024, growing at a CAGR of 16.33% during the forecast period from 2025 to 2032 to reach USD 10,315.91 million by 2032. The rapid adoption of single-use technologies, especially in biopharmaceutical manufacturing, is driven by their flexibility and efficiency, allowing quick setup for various processes to meet the growing demand for diverse bioproducts. The minimal risk of contamination between batches enhances product safety and quality, crucial in regulated environments, while also reducing cleaning and validation costs. Additionally, increased product development activities in biologics and personalized medicine require innovative manufacturing solutions for smaller batch sizes and rapid production adjustments. Collectively, these factors are expected to drive the market for single-use bioreactors, establishing them as a preferred choice in modern biomanufacturing during the forecast period from 2025 to 2032.

Single-use Bioreactors Market Dynamics:

The rapid adoption of single-use technologies in the biopharmaceutical industry is driving significant growth in the global single-use bioreactor market. This trend is fueled by key advantages such as cost efficiency, reduced contamination risk, and enhanced manufacturing flexibility. Compared to traditional stainless-steel systems, single-use bioreactors require lower capital investment and eliminate the need for extensive cleaning and validation, resulting in substantial cost savings. These benefits are particularly valuable for small biotech companies and contract manufacturing organizations (CMOs) with limited resources for large-scale infrastructure.

For example, in April 2023, Spanish CDMO mAbxience installed a 4,000 L single-use bioreactor from ABEC at its Leon facility to improve production efficiency while minimizing operational costs. Similarly, WuXi Biologics implemented multiple 4,000 L single-use bioreactors at its Wuxi facility, underscoring the industry's shift toward safer, more compliant, and scalable manufacturing solutions.

The disposable nature of single-use bioreactors significantly reduces the risk of cross-contamination between batches a critical advantage in producing sensitive biologics such as vaccines and monoclonal antibodies, where even minor contamination can lead to safety concerns and financial losses.

These factors are projected to propel the global single-use bioreactor market during the 2025-2032 forecast period. However, the increased plastic waste generated by disposable systems raises environmental concerns, which may pose a minor challenge to market growth.

Single-use Bioreactors Market Segment Analysis:

Single-use Bioreactors Market by Capacity (<=10 L, 11-100 L, 101-500 L, 501-1,500 L, and Above 1,500 L), Product (System and Accessories), Type (Stirred Tank Bioreactors, Wave-Induced Bioreactors, Bubble-Column Bioreactors, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the capacity segment of the single-use bioreactors market, bioreactors exceeding 1,500 liters are projected to capture a significant revenue share in 2024. The growing adoption of these large-capacity systems is significantly driving the market, enabling biopharmaceutical manufacturers to scale up production efficiently while benefiting from the core advantages of single-use technologies reduced contamination risk, minimized cleaning and validation requirements, and faster turnaround times.

Leading industry players like Lonza and Sartorius have made notable strides in developing large-volume single-use bioreactors to streamline the production of biologics, including monoclonal antibodies and vaccines. For example, in June 2024, WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), successfully installed three 5,000 L single-use bioreactors at its Hangzhou facility, enhancing large-scale drug substance manufacturing capabilities.

The integration of high-capacity single-use bioreactors into existing manufacturing workflows reduces the need for extensive infrastructure modifications typically associated with traditional stainless-steel systems. This operational flexibility is vital for companies aiming to optimize production without incurring significant capital expenditures. As biopharmaceutical manufacturers increasingly focus on process intensification and adopt continuous manufacturing practices, larger single-use bioreactors offer the scalability needed to achieve higher yields within shorter production cycles.

These factors of scalability, operational efficiency, and improved product quality are propelling the growth of the above 1,500 L capacity segment, thereby contributing to the overall expansion of the global single-use bioreactors market.

North America is expected to dominate the overall single-use bioreactors market:

North America is projected to hold the largest share of the global single-use bioreactors market in 2024. The region's dominance is driven by its well-established biopharmaceutical sector, with key players such as Pfizer, Moderna, and Amgen leading the adoption of advanced bioprocessing technologies. The growing focus on biologics, cell and gene therapies, and personalized medicine further fuels the demand for flexible manufacturing solutions in an area where single-use bioreactors offer significant advantages.

Regulatory support from agencies like the FDA encourages innovation, while the presence of leading manufacturers and research institutions accelerates product development. Additionally, increasing investments in biotechnology infrastructure and the expanding number of clinical trials heighten the need for scalable, cost-effective production solutions.

The surge in single-use technology adoption across North America stems from the flexibility, scalability, and operational efficiency these systems provide. Biopharmaceutical companies are leveraging single-use bioreactors for faster production setup, seamless batch transitions, and minimal contamination risk crucial for maintaining product safety and quality in highly regulated environments. Unlike traditional stainless-steel systems that require extensive cleaning and sterilization, single-use bioreactors reduce downtime and operational costs, making them particularly attractive to contract manufacturing organizations (CMOs) and smaller biotech firms.

As clinical trials and biologics manufacturing increasingly shift toward smaller batch sizes and continuous processing, the versatility of single-use systems enables companies to adapt swiftly to evolving production demands. The market's growth in the U.S. is further bolstered by new product innovations. For example, in October 2021, Agilitech a U.S.-based company launched the Agilitech bioreactor controller, capable of managing up to two single-use bioreactors with capacities ranging from 30 L to 2,000 L. Its flexible design ensures compatibility with various single-use bioreactor brands, reflecting industry-wide efforts to enhance manufacturing agility.

Collectively, these factors are expected to drive robust growth in the North American single-use bioreactors market over the forecast period.

Single-use Bioreactors Market Key Players:

Some of the key market players operating in the single-use bioreactors market include Getinge AB, Agilitech, WuXi Biologics, mAbxience, Eppendorf AG, Sartorius AG, Cytiva Life Sciences, Merck KGaA, Bionet, OmniBRx Biotechnologies, Thermo Fisher Scientific Inc., Pall Corporation, Distek, Inc., AGC Biologics, Celltainer, Applikon Biotechnology, Biolinx Labsystems, Sartorius Stedim Biotech, Solaris Biotech, Synthecon, and others.

Recent Developmental Activities in the Single-use Bioreactors Market:

  • In March 2024, Getinge AB extended the bioreactor portfolio with larger single-use systems.
  • In September 2023, Getinge AB launched a single-use bioreactor for clinical cell and gene therapies.

Key Takeaways from the Single-use Bioreactors Market Report Study

  • Market size analysis for current single-use bioreactors size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the single-use bioreactors market.
  • Various opportunities available for the other competitors in the single-use bioreactors market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current single-use bioreactors market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for single-use bioreactors market growth in the coming future?

Target Audience Who Can be Benefited from this Single-use Bioreactors Market Report Study

  • Single-use bioreactor product providers
  • Research organizations and consulting companies
  • Single-use bioreactors -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in single-use bioreactors
  • Various end-users who want to know more about the single-use bioreactors market and the latest technological developments in the single-use bioreactors market.

Frequently Asked Questions for the Single-use Bioreactors Market:

1. What are single-use bioreactors?

  • Single-use bioreactors are disposable bioprocessing systems designed for cultivating cells or microorganisms, typically used in pharmaceutical and biopharmaceutical manufacturing. They feature pre-sterilized, plastic components, reducing contamination risks and eliminating the need for cleaning, making them ideal for flexible and cost-effective production.

2. What is the market for single-use bioreactors?

  • The single-use bioreactors market was valued at USD 3,092.17 million in 2024, growing at a CAGR of 16.33% during the forecast period from 2025 to 2032 to reach USD 10,315.91 million by 2032.

3. What are the drivers for the global single-use bioreactors market?

  • The rapid adoption of single-use technologies, especially in biopharmaceutical manufacturing, is driven by their flexibility and efficiency, allowing quick setup for various processes to meet the growing demand for diverse bioproducts. The minimal risk of contamination between batches enhances product safety and quality, crucial in regulated environments, while also reducing cleaning and validation costs. Additionally, increased product development activities in biologics and personalized medicine require innovative manufacturing solutions for smaller batch sizes and rapid production adjustments. Collectively, these factors are expected to drive the market for single-use bioreactors, establishing them as a preferred choice in modern biomanufacturing during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global single-use bioreactors market?

  • Some of the key market players operating in the single-use bioreactors are Getinge AB, Agilitech, WuXi Biologics, mAbxience, Eppendorf AG, Sartorius AG, Cytiva Life Sciences, Merck KGaA, Bionet, OmniBRx Biotechnologies, Thermo Fisher Scientific Inc., Pall Corporation, Distek, Inc., AGC Biologics, Celltainer, Applikon Biotechnology, Biolinx Labsystems, Sartorius Stedim Biotech, Solaris Biotech, Synthecon, and others.

5. Which region has the highest share in the global Single-use Bioreactors market?

  • North America is expected to account for the highest proportion of the Single-use Bioreactors market in 2024, out of all regions. The region's well-established biopharmaceutical sector, with companies like Pfizer, Moderna, and Amgen, drives high adoption of advanced bioprocessing technologies, including single-use systems. Additionally, the growing focus on biologics, cell and gene therapies, and personalized medicine fuels the demand for flexible manufacturing solutions, which single-use bioreactors provide. Strong regulatory support from agencies like the FDA encourages innovation, while the presence of leading manufacturers and research institutions accelerates product development. Moreover, increasing investments in biotechnology infrastructure and the rising need for scalable production due to clinical trials further strengthen North America's leadership in the market.

Table of Contents

1. Single-use Bioreactors Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Single-use Bioreactors Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Single-use Bioreactors Market Key Factors Analysis

  • 5.1. Single-use Bioreactors Market Drivers
    • 5.1.1. The rapid adoption of single-use technologies by industries
    • 5.1.2. Minimal risk of contamination between batches
    • 5.1.3. Growing product development activities across the globe.
  • 5.2. Single-use Bioreactors Market Restraints and Challenges
    • 5.2.1. Raising environmental concerns due to the use of disposable single-use bioreactors
  • 5.3. Single-use Bioreactors Market Opportunities
    • 5.3.1. Ongoing advancements in automation and sensor technologies

6. Single-use Bioreactors Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Single-use Bioreactors Market Assessment

  • 7.1. By Capacity
    • 7.1.1. =10 L
    • 7.1.2. 11-100 L
    • 7.1.3. 101-500 L
    • 7.1.4. 501-1,500 L
    • 7.1.5. Above 1,500 L
  • 7.2. By Product
    • 7.2.1. System
    • 7.2.2. Accessories
  • 7.3. By Usage
    • 7.3.1. Stirred Tank Bioreactors
    • 7.3.2. Wave-Induced Bioreactors
    • 7.3.3. Bubble-Column Bioreactors
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.1.2. Canada Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.1.3. Mexico Single-use Bioreactors Market Size in USD Million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.2.2. Germany Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.2.3. United Kingdom Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.2.4. Italy Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.2.5. Spain Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.2.6. Rest of Europe Single-use Bioreactors Market Size in USD Million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.3.2. Japan Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.3.3. India Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.3.4. Australia Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.3.5. South Korea Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Single-use Bioreactors Market Size in USD Million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.4.2. Africa Single-use Bioreactors Market Size in USD Million (2022-2032)
      • 7.4.4.3. South America Single-use Bioreactors Market Size in USD Million (2022-2032)

8. Single-use Bioreactors Market Company and Product Profiles

  • 8.1. Getinge AB
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Agilitech
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. WuXi Biologics
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. mAbxience
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Eppendorf AG
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Sartorius AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Cytiva Life Sciences
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Merck KGaA
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Bionet
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. OmniBRx Biotechnologies
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Thermo Fisher Scientific Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Pall Corporation
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Distek, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. AGC Biologics
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Celltainer
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Applikon Biotechnology
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Biolinx Labsystems
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Sartorius Stedim Biotech
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Solaris Biotech
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Synthecon
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us